Some positive news last week when the U.S. Food and Drug Administration (FDA) approved alectinib as an adjuvant treatment for […]
Follow Us
-
+1 700 888 1234
-
Effingerstrasse 40 3008 Bern Switzerland
+1 700 888 1234
Effingerstrasse 40 3008 Bern Switzerland
Some positive news last week when the U.S. Food and Drug Administration (FDA) approved alectinib as an adjuvant treatment for […]
We’re delighted to welcome five new member organisations to our growing Lung Cancer Europe (LuCE) network. These organisations and their […]
We are delighted to announce the new Board of Lung Cancer Europe (LuCE) elected at our AGM in Zagreb last […]
Lung Cancer Europe (LuCE) Annual General Meeting and General Assembly The Lung Cancer Europe (LuCE) AGM and General Assembly take […]
Bristol Myers Squibb has released a new Press Release announcing that the European Medicines Agency (EMA) has validated the marketing authorization application for repotrectinib. Repotrectinib […]
consectetur adipisicing elit, sed do eiusmod tempor incididunt laboret dolore magna aliqua. Ut enim minim veniam quis nostrud exercitation ullamco laboris.
Website Under Construction
We are currently rebuilding our website, and look forward to its launch later in 2026.
Until then, this website is not being updated. Feel free to continue browsing, or visit our news site for the latest updates.
